Results 191 to 200 of about 45,438 (256)

The Illness Narratives of Children and Young People With Spinal Muscular Atrophy: A Scoping Review

open access: yesJournal of Advanced Nursing, EarlyView.
ABSTRACT Aim(s) This review seeks to explore the illness narratives of children and young people focusing on their healthcare trajectories; the right to health; and the kind of stories told about them. Design This scoping review adopts a narrative approach to analyse how the illness experience of Spinal Muscular Atrophy is represented in the literature,
Marcela González‐Agüero   +6 more
wiley   +1 more source

Changes in the cortical GABAergic inhibitory system in a Spinal Muscular Atrophy mouse model. [PDF]

open access: yesCell Death Dis
Menduti G   +10 more
europepmc   +1 more source

Vectors and Vector‐Borne Diseases: Biology, Epidemiology and Integrated Control Strategies

open access: yesJournal of Applied Entomology, EarlyView.
ABSTRACT Vector‐Borne Diseases (VBDs), transmitted by arthropods such as mosquitoes, ticks, fleas and sandflies, represent a significant threat to global health. These diseases can be caused by a variety of pathogens, including bacteria, viruses, protozoa, and helminths.
Roberta Rinaldi   +4 more
wiley   +1 more source

Cyclin‐dependent kinase 13 is indispensable for normal mouse heart development

open access: yesJournal of Anatomy, Volume 246, Issue 4, Page 616-630, April 2025.
Congenital heart disease (CHD) is the most common defect in live births. The role of cyclin‐dependent kinase (CDK13) in cardiogenesis and CHD was studied using a transgenic mouse model (Cdk13tm1b) carrying deletion of exons 3 and 4, causing loss of function.
Qazi Waheed‐Ullah   +8 more
wiley   +1 more source

Assessment of safety and efficacy of risdiplam treatment in adults with spinal muscular atrophy. [PDF]

open access: yesFront Neurol
Jaworek A   +12 more
europepmc   +1 more source

Hip displacement management in spinal muscular atrophy in the era of disease modifying therapies: a Delphi consensus study in the UK. [PDF]

open access: yesEClinicalMedicine
Vanegas MI   +4 more
europepmc   +1 more source

High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial. [PDF]

open access: yesNat Med
Finkel RS   +18 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy